Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05239143 · ClinicalTrials.gov registry record · Phase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Poseida Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 14
- Study locations
NCT05239143: Active Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Poseida Therapeutics.
NCT05239143 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Poseida Therapeutics. The registered enrollment target is 180 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05239143, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Poseida Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Primary Outcome
Number of subjects with a dose limiting toxicity (DLT)
Conditions Studied
Interventions
- DRUG Rimiducid
- BIOLOGICAL P-MUC1C-ALLO1 CAR-T cells
Study Locations (14)
California
- University of California, Irvine Medical Center - Irvine
- Cedars Sinai Medical Center - Los Angeles
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Kansas
- University of Kansas Cancer Center - Westwood
- Cancer Center of Kansas - Wichita
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- University of Maryland Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2039-04 |
| Phase | Phase 1 |
What the registry record for NCT05239143 still lists
NCT05239143 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Rimiducid is the first listed.
NCT05239143 lists 14 locations in 9 states (California, Kansas, Texas).
Frequently Asked Questions
What is clinical trial NCT05239143 about?
NCT05239143 is a clinical study titled "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors". A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
What is the current status of trial NCT05239143?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2022-02-15. Estimated completion is 2039-04.
What conditions does trial NCT05239143 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT05239143?
The interventions under investigation include: Rimiducid (DRUG), P-MUC1C-ALLO1 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05239143?
This trial is sponsored by Poseida Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05239143 being conducted?
This trial has 14 study locations across California, Colorado, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05239143's enrollment target sits among peer trials
180 406th of 1224 higher than 817 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI